TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
BOSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported further steps in its previously-announced restructuring. The restructuring is intended to further reduce expenditures and enable greater concentration of company resources on a planned Phase 1 clinical trial for its lead therapeutic candidate, TTX-MC138. The restructuring follows a strategic review of the company’s operations to identify areas in which it could delay or reduce expenditures, including a previously announced reduction in headcount.
Related news for (RNAZ)
- Breaking News: MoBot’s Latest Update as of 07/23/25 12:00 PM
- MoBot’s Stock Market Highlights – 07/23/25 11:00 AM
- TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board
- TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported
- TransCode Therapeutics Announces 1-for-28 Reverse Stock Split